Benazepril combining irbesartan in treatment of early diabetic nephropathy
Yang Li
LV Xiao-feng
CHANG Kuai-le
Abstract：Objective To study the influences of benazepril combining irbesartan on kidney function, adiponectin (APN) and high-sensitivity C-reactive protein (hs-CRP) in the patients with early diabetic nephropathy (DN). Methods The early DN patients (n=84) accompanied by grade 1 hypertension were chosen from the Department of Endocrinology of the General Hospital of PLA Beijing Military Area Command from Jan. 2011 to Jun. 2012, and randomly divided into routine group and combining group (each n=42). The routine group was given benazepril (10 mg-20 mg) and combining group was given benazepril (10 mg) and irbesartan (150 mg-300 mg) all for three months. The changes of endogenous creatinine clearance rate (Ccr) and 24 h-UPE, and levels of plasma APN and hs-CRP were compared in two group before and after treatment. Results The levels of Ccr and plasma APN increased significantly and levels of 24 h-UPE and hs-CRP decreased significantly in two groups after treatment (P<0.05). Compared with routine group, the levels of 24 h-UPE and hs-CRP were higher and levels of Ccr and plasma APN were lower in combining group (P<0.05). Conclusion Benazepril combining irbesartan can protect the kidney function in the patients with early DN, which may be related to the improvement of vascular endothelial function and antagonism of inflammatory reactions.
Keywords：BenazeprilIrbesartanDiabetic nephropathyHigh-sensitivity C-reactive proteinAdiponectin
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 467-469 )